JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
128.06
-0.74 (-0.57%)
As of 10:36AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close128.80
Open128.50
Bid128.48 x 800
Ask128.50 x 1200
Day's Range127.93 - 129.29
52 Week Range118.62 - 148.99
Volume1,671,427
Avg. Volume9,925,416
Market Cap343.454B
Beta (3Y Monthly)0.62
PE Ratio (TTM)225.06
EPS (TTM)0.57
Earnings DateApr 16, 2019
Forward Dividend & Yield3.60 (2.79%)
Ex-Dividend Date2019-02-25
1y Target Est145.39
Trade prices are not sourced from all markets
  • Johnson & Johnson earnings beat expectations but signal slowing sales
    Yahoo Finance Video21 hours ago

    Johnson & Johnson earnings beat expectations but signal slowing sales

    Johnson & Johnson warns of sluggish sales in 2019. Yahoo Finance's Adam Shapiro, Emily McCormick, Rick Newman, Ethan Wolff-Mann and Tendayi Kapfidze LendingTree Chief Economist discuss.

  • J&J's talc powder controversy won't be a 'major challenge...
    CNBC Videos14 hours ago

    J&J's talc powder controversy won't be a 'major challenge...

    Damien Conover of Morningstar weighs in on Johnson & Johnson's talcum powder controversy and its impact on the company. He also says the firm could use asset divestiture to boost earnings or revenues in 2019.

  • Company News For Jan 23, 2019
    Zacks1 hour ago

    Company News For Jan 23, 2019

    Companies In The News Are: JNJ,SWK,ARNC,BG

  • Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
    Zacks1 hour ago

    Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

    AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.

  • J&J Reportedly Mulls $2 Billion Buyout Of Intuitive Surgical Rival
    Investor's Business Daily1 hour ago

    J&J Reportedly Mulls $2 Billion Buyout Of Intuitive Surgical Rival

    Johnson & Johnson is reportedly considering a bid for Auris Health, a privately held robotic surgery firm with a lung cancer biopsy tool that rivals Intuitive Surgical's not-yet-cleared Ion.

  • Johnson & Johnson or Abbott Laboratories: Who Has Better Margins?
    Market Realist2 hours ago

    Johnson & Johnson or Abbott Laboratories: Who Has Better Margins?

    How Johnson & Johnson and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidance In its third-quarter earnings conference call, Johnson & Johnson (JNJ) has forecasted YoY improvement of at least 150 basis points in pre-tax

  • CNBC3 hours ago

    Stocks making the biggest moves premarket: Comcast, Walmart, IBM & more

    The NBCUniversal and CNBC parent reported adjusted quarterly profit of 64 cents per share, beating consensus estimates by 2 cents a share. United Technologies UTX – The maker of Carrier air conditioners, Otis elevators, and a wide variety of other industrial products reported adjusted quarterly profit of $1.95 per share, well above the consensus estimate of $1.53 a share. Revenue also came in above analysts' forecasts, boosted by the company's November acquisition of defense contractor Rockwell Collins.

  • Reuters3 hours ago

    J&J eyeing surgical robotics firm Auris Health - Bbg

    J&J is seeking to purchase Auris at a premium to the valuation from its latest funding round that valued the company at $2 billion, Bloomberg reported. The final deal has not been reached and there is no certainty that the deliberations will lead to a sale of Auris, according to Bloomberg. J&J declined to comment while Auris could not be immediately reached for comment.

  • Reuters3 hours ago

    J&J eyeing surgical robotics firm Auris Health - Bbg

    Johnson & Johnson is pursuing an acquisition of surgical robotics firm Auris Health Inc, Bloomberg reported on Wednesday, citing people with knowledge of the matter. J&J is seeking to purchase Auris at a premium to the valuation from its latest funding round that valued the company at $2 billion, Bloomberg reported https://bloom.bg/2RG9kwA. The final deal has not been reached and there is no certainty that the deliberations will lead to a sale of Auris, according to Bloomberg.

  • JNJ or ABT: Who Is on a Better Earnings Growth Trajectory?
    Market Realist3 hours ago

    JNJ or ABT: Who Is on a Better Earnings Growth Trajectory?

    How Johnson & Johnson and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings guidance In its third-quarter earnings conference call, Johnson & Johnson (JNJ) has forecasted its fiscal 2018 adjusted EPS to be $8.13–$8.18, which

  • CNBC4 hours ago

    Stocks to rise | Davos rolls on | Shutdown enters Day 33

    The Tuesday slide also marked the first decline for the Dow, S&P 500, and Nasdaq in five sessions. Dow stock IBM (IBM) was jumping about 6 percent in premarket trading after the company reported adjusted quarterly profit of $4.87 per share, 5 cents above consensus. After-the-bell reports this afternoon will come from Citrix Systems (CTXS), Ford Motor (F), F5 Networks (FFIV), Las Vegas Sands (LVS), Texas Instruments (TXN), and Xilinx (XLNX).

  • Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript
    Motley Fool12 hours ago

    Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript

    JNJ earnings call for the period ending December 31, 2018.

  • Thomson Reuters StreetEvents14 hours ago

    Edited Transcript of JNJ earnings conference call or presentation 22-Jan-19 1:30pm GMT

    Q4 2018 Johnson & Johnson Earnings Call

  • The Wall Street Journal15 hours ago

    [$$] Another Reason to Worry About Johnson & Johnson

    Concerns about potential product liability from contamination of Johnson & Johnson’s baby powder sparked a nasty selloff in the company’s stock late last year. Fourth-quarter results from J&J on Tuesday highlight a more immediate risk: slowing growth. The range implies little or no sales growth this year and its shares fell in morning trading.